232 related articles for article (PubMed ID: 11853157)
1. Gastrointestinal transit and drug absorption.
Kimura T; Higaki K
Biol Pharm Bull; 2002 Feb; 25(2):149-64. PubMed ID: 11853157
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of absorption kinetics of orally administered theophylline in rats based on gastrointestinal transit monitoring by gamma scintigraphy.
Haruta S; Kawai K; Jinnouchi S; Ogawara KI; Higaki K; Tamura S; Arimori K; Kimura T
J Pharm Sci; 2001 Apr; 90(4):464-73. PubMed ID: 11170036
[TBL] [Abstract][Full Text] [Related]
3. Analysis and prediction of absorption behavior for theophylline orally administered as powders based on gastrointestinal-transit-absorption (Gita) model.
Kadono K; Yokoe J; Ogawara K; Higaki K; Kimura T
Drug Metab Pharmacokinet; 2002; 17(4):307-15. PubMed ID: 15618682
[TBL] [Abstract][Full Text] [Related]
4. Prediction of the plasma concentration profiles of orally administered drugs in rats on the basis of gastrointestinal transit kinetics and absorbability.
Sawamoto T; Haruta S; Kurosaki Y; Higaki K; Kimura T
J Pharm Pharmacol; 1997 Apr; 49(4):450-7. PubMed ID: 9232547
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of in vivo dissolution behavior and GI transit of griseofulvin, a BCS class II drug.
Fujioka Y; Metsugi Y; Ogawara K; Higaki K; Kimura T
Int J Pharm; 2008 Mar; 352(1-2):36-43. PubMed ID: 18037251
[TBL] [Abstract][Full Text] [Related]
6. Analysis and prediction of absorption behavior of colon-targeted prodrug in rats by GI-transit-absorption model.
Yokoe J; Iwasaki N; Haruta S; Kadono K; Ogawara K; Higaki K; Kimura T
J Control Release; 2003 Jan; 86(2-3):305-13. PubMed ID: 12526826
[TBL] [Abstract][Full Text] [Related]
7. Prediction of plasma concentration-time curve of orally administered theophylline based on a scintigraphic monitoring of gastrointestinal transit in human volunteers.
Haruta S; Kawai K; Nishii R; Jinnouchi S; Ogawara Ki; Higaki K; Tamura S; Arimori K; Kimura T
Int J Pharm; 2002 Feb; 233(1-2):179-90. PubMed ID: 11897422
[TBL] [Abstract][Full Text] [Related]
8. Prediction of oral absorption of griseofulvin, a BCS class II drug, based on GITA model: utilization of a more suitable medium for in-vitro dissolution study.
Fujioka Y; Kadono K; Fujie Y; Metsugi Y; Ogawara K; Higaki K; Kimura T
J Control Release; 2007 Jun; 119(2):222-8. PubMed ID: 17442444
[TBL] [Abstract][Full Text] [Related]
9. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.
Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C
Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464
[TBL] [Abstract][Full Text] [Related]
10. Analysis and prediction of absorption profile including hepatic first-pass metabolism of N-methyltyramine, a potent stimulant of gastrin release present in beer, after oral ingestion in rats by gastrointestinal-transit-absorption model.
Kimura T; Iwasaki N; Yokoe JI; Haruta S; Yokoo Y; Ogawara KI; Higaki K
Drug Metab Dispos; 2000 May; 28(5):577-81. PubMed ID: 10772638
[TBL] [Abstract][Full Text] [Related]
11. Absorption behavior of orally administered drugs in rats treated with propantheline.
Haruta S; Iwasaki N; Ogawara K; Higaki K; Kimura T
J Pharm Sci; 1998 Sep; 87(9):1081-5. PubMed ID: 9724558
[TBL] [Abstract][Full Text] [Related]
12. Site of drug absorption after oral administration: assessment of membrane permeability and luminal concentration of drugs in each segment of gastrointestinal tract.
Masaoka Y; Tanaka Y; Kataoka M; Sakuma S; Yamashita S
Eur J Pharm Sci; 2006 Nov; 29(3-4):240-50. PubMed ID: 16876987
[TBL] [Abstract][Full Text] [Related]
13. Gastrointestinal dynamics and pharmacology for the optimum design of controlled-release oral dosage forms.
Read NW; Sugden K
Crit Rev Ther Drug Carrier Syst; 1988; 4(3):221-63. PubMed ID: 3276406
[TBL] [Abstract][Full Text] [Related]
14. Drug absorption in gastrointestinal disease with particular reference to malabsorption syndromes.
Parsons RL
Clin Pharmacokinet; 1977; 2(1):45-60. PubMed ID: 322910
[TBL] [Abstract][Full Text] [Related]
15. A Quantitative Review and Meta-models of the Variability and Factors Affecting Oral Drug Absorption-Part II: Gastrointestinal Transit Time.
Abuhelwa AY; Foster DJR; Upton RN
AAPS J; 2016 Sep; 18(5):1322-1333. PubMed ID: 27439620
[TBL] [Abstract][Full Text] [Related]
16. Explaining variable absorption of a hypolipidemic agent (CGP 43371) in healthy subjects by gamma scintigraphy and pharmacokinetics.
Sun JX; Walter B; Sandefer EP; Page RC; Digenis GA; Ryo UY; Cipriano A; Maniara WM; Powell ML; Chan K
J Clin Pharmacol; 1996 Mar; 36(3):230-7. PubMed ID: 8690816
[TBL] [Abstract][Full Text] [Related]
17. PBPK models for the prediction of in vivo performance of oral dosage forms.
Kostewicz ES; Aarons L; Bergstrand M; Bolger MB; Galetin A; Hatley O; Jamei M; Lloyd R; Pepin X; Rostami-Hodjegan A; Sjögren E; Tannergren C; Turner DB; Wagner C; Weitschies W; Dressman J
Eur J Pharm Sci; 2014 Jun; 57():300-21. PubMed ID: 24060672
[TBL] [Abstract][Full Text] [Related]
18. [Quantitative Analysis of Gastrointestinal Physiology for Better Prediction of Oral Drug Absorption and Interaction].
Shirasaka Y
Yakugaku Zasshi; 2020; 140(5):599-608. PubMed ID: 32378658
[TBL] [Abstract][Full Text] [Related]
19. Relationship between the rate of appearance of oxprenolol in the systemic circulation and the location of an oxprenolol Oros 16/260 drug delivery system within the gastrointestinal tract as determined by scintigraphy.
Davis SS; Washington N; Parr GD; Short AH; John VA; Lloyd P; Walker SM
Br J Clin Pharmacol; 1988 Oct; 26(4):435-43. PubMed ID: 3056482
[TBL] [Abstract][Full Text] [Related]
20. Food, gastrointestinal pH, and models of oral drug absorption.
Abuhelwa AY; Williams DB; Upton RN; Foster DJ
Eur J Pharm Biopharm; 2017 Mar; 112():234-248. PubMed ID: 27914234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
